Károly Palatka

Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort

K Gecse, Barbara D. Lovász, Klaudia Farkas et al. · Journal of Crohn s and Colitis · 2015 · 182 citations · Full text

Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s disease

László Kiss, Tamás Szamosi, Tamás Molnár et al. · Alimentary Pharmacology & Therapeutics · 2011 · 159 citations · Full text

New Serological Markers for Inflammatory Bowel Disease Are Associated With Earlier Age at Onset, Complicated Disease Behavior, Risk for Surgery, and NOD2/CARD15 Genotype in a Hungarian IBD Cohort

Mária Papp, I Altorjay, Nir Dotan et al. · The American Journal of Gastroenterology · 2008 · 146 citations

Peripheral blood gene expression patterns discriminate among chronic inflammatory diseases and healthy controls and identify novel targets

Bertalan Meskó, Szilard Poliskal, Andrea Szegedi et al. · BMC Medical Genomics · 2010 · 117 citations · Full text

Predictors of relapse in patients with Crohn's disease in remission after 1 year of biological therapy

Tamás Molnár, Péter L. Lakatos, Klaudia Farkas et al. · Alimentary Pharmacology & Therapeutics · 2012 · 85 citations · Full text